CGRP-targeted preventive therapy
Medication targeting the CGRP pathway implicated in migraine attacks, used to reduce attack frequency rather than treat an attack already underway.
What it is & how it works
Medication (monoclonal antibody or oral “gepant”) targeting the calcitonin gene-related peptide (CGRP) pathway implicated in migraine attacks, used to reduce attack frequency rather than treat an attack already underway.
How it's done
Typically administered as a monthly (or in some cases quarterly) subcutaneous self-injection, or, for one option, an intravenous infusion every three months, prescribed and monitored by the treating physician, with response typically assessed over the first two to three months of use.
Conditions it treats
Why Brain Bridge
Selected individually based on the patient's diagnosed frequency and severity, in keeping with Brain Bridge's individualized-planning approach rather than a one-size-fits-all preventive default.
Evidence & safety
Selected individually based on frequency and severity of migraine attacks.
Related questions
The most frequently reported is constipation; injection-site reactions and, less commonly, hair thinning have also been reported. Most people tolerate these medications well, with side-effect rates that are generally lower than many older oral preventive options.
CGRP-targeted preventive therapy is taken on a schedule to reduce how often attacks happen. It's a different drug class from triptans or other medications used to treat an attack already underway, and the two are often used together.